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Abstract
Intravascular large B-cell lymphoma (IVLBCL) is a rare (<1%), typically aggressive extranodal
variant of mature non-Hodgkin B-cell lymphoma. IVLBCL is characterized by malignant lymphoid
cells lodged within blood vessels, particularly capillary channels. Herein, we present a case of a
50-year-old man with a history of myeloradiculitis (1 year) and paraparesis requiring hospital-
ization. During the course of his hospital stay, computed tomography (CT), magnetic resonance
imaging, CT-positron emission tomography, and biopsy failed to establish a diagnosis. The patient
died 2 months later from bilateral pneumonia. Postmortem examination was undertaken to
determine the cause of death. Histologic sections of the patient’s brain, heart, lung, and liver
showed aggregates of highly atypical cells bearing enlarged, pleomorphic, and hyperchromatic
nuclei. Strong intravascular positivity for CD45 and CD20 markers indicated the cells were of
B-cell origin, supporting a diagnosis of IVLBCL.
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Introduction
The latest World Health Organization dis-
ease classification revisions define intravas-
cular large B-cell lymphoma (IVLBCL) as a
rare subtype of diffuse large B-cell lympho-
ma. This malignancy may be difficult to
diagnose clinically, sometimes requiring
autopsy.1 Patients tend to present with a
confusing symptom complex, signaling
vascular occlusive organ dysfunction, or
with systemic manifestations such as unex-
plained fever.2,3
The current case had a complex clinical
presentation and diagnostic difficulties. An
accurate diagnosis was only finally achieved
following postmortem examination, based
on immunohistochemical staining.
Case report
The patient was a 50-year-old Caucasian
man with a history of myeloradiculitis
(1 year) who was ultimately hospitalized
for paraparesis. No specific lesions or other
pathology were detected by total-body
computed tomography (CT). A whole-
body 18-fluorodeoxyglucose positron emis-
sion tomography (PET) scan indicated
greater uptake by the adrenal glands and
in an area of mesenteric fat (Figure 1a).
Serologic tests for infection and autoimmune
markers were negative. During the first hos-
pitalization, blood biochemistry analysis
showed a lactate dehydrogenase level of
465UI/L (normal value < 250UI/L),
C-reactive protein level of 35.9mg/L
(normal value <50mg/L), and beta-2 globu-
lin 6.2% (normal value 3.1% to 6.0%).
Magnetic resonance imaging (MRI) of the
lumbar spine (with and without gadolinium
contrast) showed swelling of the conus
medullaris (T11–L1), T2-weighted hyperin-
tensities of the anterior and posterior cord,
and vasogenic edema (Figure 1b, 1c).
Bone marrow biopsy was obtained
but was unrevealing, and flow cytometry
produced no immunophenotypic signs of
Figure 1. (a) 18-Fluorodeoxyglucose positron emission tomography scan indicated (red arrows and ring)
greater uptake by adrenal glands. (b, c) Magnetic resonance imaging of lumbar spine showed swelling of the
conus medullaris (T11–L1), T2-weighted hyperintensities of anterior and posterior cord, and vasogenic
edema.
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clonal cell expansion. Biopsy of the spinal
cord disclosed tissue necrosis, with macro-
phage infiltrates (CD68þ) and reactive
gliosis, but chromogenic reactivity for
microtubule-associated protein 2 was lack-
ing. A dermatologic consultant found no
suspicious melanocytic lesions.
The patient developed a pulmonary
thromboembolism during hospitalization
and his condition progressively worsened.
He died of bilateral pneumonia 2 months
after the development of thromboembolism.
Postmortem examination was subse-
quently conducted to establish the cause
of death. Gross inspection found no focal
changes in the spinal cord, only a palpable
loss of consistency. Histologic sections of
vital organs (brain, heart, lung, and liver)
revealed intravascular accumulations of
highly atypical cells with enlarged, pleo-
morphic, and hyperchromatic nuclei, chiefly
confined to the blood vessels, but also scat-
tered focally in the heart and liver intersti-
tium. Endothelial lymphocytic infiltrates
were also observed (Figure 2a).
We performed immunohistochemical
staining with a panel of antibodies targeting
cytokeratins (CK7, CK20), lymphocyte anti-
gens (CD3, CD20, CD45), programmed
death-ligand 1 (PD-L1), muscle creatinine
kinase (MCK), and thyroid transcription
factor 1 (TTF1). Strong intravascular CD20
and CD45 positivity indicated the cells were
of B-cell origin, supporting a diagnosis of
IVLBCL (Figures 2b, 2c). There was slight
intravascular PD-L1 positivity, and evident
endothelial CD3 positivity (Figures 2d, 2e).
All other markers (CK7, CK20, MCK, and
TTF1) were negative (Figures 2f–2h).
Discussion
IVLBCL is characterized by malignant lym-
phoid proliferations within blood vessels,
particularly capillaries. This uncommon
(<1%) extranodal form of mature non-
Hodgkin B-cell lymphoma tends to behave
aggressively and can involve any organ in
the body. Although previous reports have
indicated that the usual manifestations
Figure 2. Microscopic features of intravascular large B-cell lymphoma. (a) Pleomorphic, highly atypical cells
within blood vessels in the brain and endothelial lymphocytic infiltrate (red arrows) (hematoxylin and eosin,
40). (b, c) Strong intravascular positivity for CD20 and CD45 (brown reactions) (40); (d) CD3 positivity
(red arrows) of endothelial infiltrate (40); (e) slight intravascular positivity for PD-L1 (red arrows) (40);
and (f–h) negative reactions for CK7, TTF-1, and MCK (40).
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involve neurologic signs and symptoms,2,3
the neuropathic expressions may vary,
including mental status alterations, brief
ischemic attacks, deficient motor functions,
and paraparesis.4 Most patients (76%) are
prone to central nervous system (CNS)
problems as the disease progresses, often
(38%) originating in the spinal cord and
nerve roots, whereas some patients (25%)
show CNS involvement at presentation.5–9
Despite the known potential for false
negative results, contrast-enhanced whole-
body CT and whole-brain MRI scans,
cerebrospinal fluid cytology, peripheral
blood smears, bone marrow biopsy, and
biochemical blood testing are the recom-
mended diagnostic methods for IVLBCL.
Postmortem immunohistochemical staining
should target CD20, CD45, and PD-L1
markers.10
The current case highlights the limita-
tions of standard diagnostic imaging (CT,
MRI, and CT-PET) in this particular set-
ting. Testing biopsy samples using a battery
of key immunohistochemical stains may
thus be the best diagnostic strategy in
patients with suspected IVLBCL.11,12
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